BACKGROUND: The amyloid neuritic plaque is considered to be a toxic collection of amyloid-ss protein found in brain tissue in Alzheimer's disease. A neutral analogue of the amyloid-binding thioflavin-T (BTA), has been radiolabeled as [C-11]-6-OH-BTA-1. It crosses the blood brain barrier, and is a promising tracer for imaging plaques in vivo using positron emission tomography. We now report the biodistribution and dosimetry of [C-11]-6-OH-BTA-1 in baboons. METHODS: Four 2-hour whole body studies were acquired in an ECAT ACCEL camera in two baboons after the bolus injection of [C-11]-6-OH-BTA-1. After 3.5 minute transmission scans performed per bed position prior to injection, emission scans were collected in 2-D mode over five bed positions. Regions of interest (ROI) were drawn around the brain, left and right lungs, heart, liver, gall bladder, left and right kidneys, spleen and urinary bladder. Since no fluid was removed from the baboons, total body radioactivity was calculated using the injected dose and a calibration factor determined from a cylinder phantom. The area under the curve (AUC) for each ROI was determined by trapezoidal integration of the first few points with subsequent points fit by a decreasing monoexponential. The AUC was then divided by counts in the total body, and resulting residence times were entered into the MIRDOSE3 program. RESULTS: The animals tolerated the procedure well. The ligand was eliminated via the hepatobiliary and renal systems. In the adult male and female reference the gallbladder received the highest estimated radiation dose and was the critical organ (3.9E-02 mGy/MBq and 4.3E-02 mGy/MBq respectively). CONCLUSION: In the United States, the absorbed dose to the gallbladder would limit [C-11]-6-OH-BTA-1 administered with the approval of a Radioactive Drug Research Committee (RDRC) to a single injection of 1295 MBq (35 mCi) in the adult male, and 1314 MBq (35 mCi) in the adult female.
BACKGROUND: The amyloid neuritic plaque is considered to be a toxic collection of amyloid-ss protein found in brain tissue in Alzheimer's disease. A neutral analogue of the amyloid-binding thioflavin-T (BTA), has been radiolabeled as [C-11]-6-OH-BTA-1. It crosses the blood brain barrier, and is a promising tracer for imaging plaques in vivo using positron emission tomography. We now report the biodistribution and dosimetry of [C-11]-6-OH-BTA-1 in baboons. METHODS: Four 2-hour whole body studies were acquired in an ECAT ACCEL camera in two baboons after the bolus injection of [C-11]-6-OH-BTA-1. After 3.5 minute transmission scans performed per bed position prior to injection, emission scans were collected in 2-D mode over five bed positions. Regions of interest (ROI) were drawn around the brain, left and right lungs, heart, liver, gall bladder, left and right kidneys, spleen and urinary bladder. Since no fluid was removed from the baboons, total body radioactivity was calculated using the injected dose and a calibration factor determined from a cylinder phantom. The area under the curve (AUC) for each ROI was determined by trapezoidal integration of the first few points with subsequent points fit by a decreasing monoexponential. The AUC was then divided by counts in the total body, and resulting residence times were entered into the MIRDOSE3 program. RESULTS: The animals tolerated the procedure well. The ligand was eliminated via the hepatobiliary and renal systems. In the adult male and female reference the gallbladder received the highest estimated radiation dose and was the critical organ (3.9E-02 mGy/MBq and 4.3E-02 mGy/MBq respectively). CONCLUSION: In the United States, the absorbed dose to the gallbladder would limit [C-11]-6-OH-BTA-1 administered with the approval of a Radioactive Drug Research Committee (RDRC) to a single injection of 1295 MBq (35 mCi) in the adult male, and 1314 MBq (35 mCi) in the adult female.
Authors: D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey Journal: J Geriatr Psychiatry Neurol Date: 2010-04-29 Impact factor: 2.680
Authors: Anniina Snellman; Johanna Rokka; Francisco R Lopez-Picon; Olli Eskola; Ian Wilson; Gill Farrar; Mika Scheinin; Olof Solin; Juha O Rinne; Merja Haaparanta-Solin Journal: Eur J Nucl Med Mol Imaging Date: 2012-07-17 Impact factor: 9.236
Authors: Dileep J S Kumar; Bing Bai; Hanna H Ng; Jon C Mirsalis; Kjell Erlandsson; Matthew S Milak; Vattoly J Majo; Jaya Prabhakaran; J J Mann; R V Parsey Journal: Int J Toxicol Date: 2011-10-12 Impact factor: 2.032
Authors: Tuula Tolvanen; Timo Yli-Kerttula; Tiina Ujula; Anu Autio; Pertti Lehikoinen; Heikki Minn; Anne Roivainen Journal: Eur J Nucl Med Mol Imaging Date: 2010-01-13 Impact factor: 9.236
Authors: Arthur Mikhno; Davangere Devanand; Gregory Pelton; Katrina Cuasay; Roger Gunn; Neil Upton; Robert Y Lai; Vincenzo Libri; J John Mann; Ramin V Parsey Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Martin J Lan; R Todd Ogden; Dileep Kumar; Yaakov Stern; Ramin V Parsey; Gregory H Pelton; Harry Rubin-Falcone; Gnanavalli Pradhaban; Francesca Zanderigo; Jeffrey M Miller; J John Mann; D P Devanand Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Anu Autio; Helena Virtanen; Tuula Tolvanen; Heidi Liljenbäck; Vesa Oikonen; Tiina Saanijoki; Riikka Siitonen; Meeri Käkelä; Andrea Schüssele; Mika Teräs; Anne Roivainen Journal: EJNMMI Res Date: 2015-07-17 Impact factor: 3.138